DR polymorphisms have been shown to be associated with the risk of colorectal cancer, non-small-cell lung cancer, and gastric cancer, and increased expression of dopamine D2 receptors (DR2) has been observed in gastric cancer, neuroendocrine tumors, glioma, and breast cancer [64,65,66,67,68]. This evidence concerns the gene DRD2 and gastric cancer.